Correlation of β-catenin expression in non-small cell lung cancer to prognosis and CD8 positive cells infiltration. This is an ASCO Meeting Abstract from the 2018 ASCO-SITC Clinical Immuno-Oncology ...

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma. The assay is now ...

The preventive effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors. Precision medicine-based ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union. PD-L1 expression ...

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ ...

CARPINTERIA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its Dako PD-L1 IHC 22C3 pharmDx now has an expanded label approved by the U.S. Food and Drug ...

Announcement marks the seventh cancer type for which PD-L1 IHC 22C3 pharmDx has gained approval in the US SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it ...

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx (SK006) SANTA CLARA, ...

Agilent Technologies A has bolstered presence in the clinical and diagnostic testing market of Europe by expanding the use of PD-L1 IHC 22C3 pharmDx assay in patients suffering from esophageal cancer ...

Agilent Technologies Inc. announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying esophageal cancer ...